xten peptide is fused to a protein drug, using recombinant technology - Multivalent antiviralxten peptideconjugates with long in vivo half life and enhanced solubility extended recombinant polypeptide (XTEN) compositions XTEN Peptide: Revolutionizing Drug Delivery with Extended Half-Life and Enhanced Efficacy

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner The field of pharmaceutical development is constantly seeking innovative ways to improve the efficacy and delivery of therapeutic agents. Among the most promising advancements is the development of XTEN peptide technology, a novel approach that significantly extends the in vivo half-life of peptides and proteins. This groundbreaking polypeptide platform offers a compelling alternative to traditional methods like PEGylation, addressing limitations and opening new avenues for drug development2013年1月23日—The long, biodegradable XTEN polypeptideis fused to a protein drug, using recombinant technology, or to a peptide, protein or other molecule ....

XTEN peptide: a biological alternative to PEGylation, XTEN is a class of unstructured, hydrophilic, and biodegradable protein polymers specifically designed to increase the half-lives of therapeutic peptides and proteins. Unlike conventional methods, XTEN peptide technology leverages naturally occurring amino acids to create these extended recombinant polypeptide molecules.作者：A Haeckel·2016·被引用次数：47—Crucial for this goal was the novel unstructured polypeptide XTEN, whichacts like polyethylene glycol (PEG) but has many important advantages. This means that a polypeptide XTEN can be genetically fused to a therapeutic protein or peptide, enhancing its pharmacokinetic profile without compromising its biological activity.

The core innovation behind XTEN peptide lies in its unique structure and properties.The present invention relates toextended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to ... These unstructured, nonrepetitive protein polymers possess a large hydrodynamic volume and a negative charge, which contribute to their ability to prolong the circulation time of fused molecules. This "bulking effect" is crucial for extending the in vivo half-life, allowing for less frequent dosing and potentially improving patient compliance and treatment outcomesXTENylation Service. Furthermore, XTEN is designed to be nonimmunogenic, a critical factor for therapeutic applications, as demonstrated by studies where exenatide–XTEN showed no adverse effects and was not strongly immunogenic.

The versatility of XTEN peptide technology is evident in its broad applicability. Research has shown that XTEN can be used to extend the half-life of various biologically active molecules, including imaging probes like annexin A5.Here, we apply a new hydrophilicpolypeptide XTENto extend the blood half-life of an imaging probe. As an example, we chose annexin A5 (AnxA5), a recombinant ... In one study, the fusion of an unstructured recombinant polypeptide of 864 amino acids, known as XTEN, to a peptide or protein provided a seemingly generic method for half-life extension. This suggests that XTEN can be a valuable tool for a wide spectrum of pharmaceutical applications, from therapeutic proteins to diagnostic agents.

The construction of XTEN polypeptide molecules is based on hydrophilic amino acid building blocks, specifically A, E, G, P, S, and T. This precise composition ensures high chemical and physical stability, making them suitable for various formulation and delivery strategies. This meticulous design allows for tunable half-life extension, providing researchers with control over the pharmacokinetic properties of their drug candidatesGLP2-2G-XTEN: A Pharmaceutical Protein with Improved .... The development of extended recombinant polypeptide (XTEN) compositions and conjugate compositions comprising XTEN linked to other molecules further underscores its adaptability.

Beyond therapeutic applications, XTEN peptide technology is also finding its way into advanced material science. For instance, genetically encoded XTEN-based hydrogels with tunable properties have been developed. These shear-thinning and self-healing hydrogels, designed around XTEN, highlight the material's potential beyond drug delivery, showcasing its capacity for creating sophisticated biomaterials.XTEN-Annexin A5: XTEN Allows Complete Expression of ...

The significance of XTEN peptide in modern biotechnology is further emphasized by its comparison to other half-life extension strategies. While the Albumin-binding domain (ABD) is another common approach, the XTEN polypeptide offers a distinct and often more potent method for achieving prolonged circulation times作者：SE Alters·2012·被引用次数：89—Glucagon-like peptide 2 (GLP2) is an intestinal growth factor that has been shown to stimulate intestinal growth and reduce disease severity in preclinical .... Studies have shown that the fusion of XTEN to peptide drugs can result in half-life extensions of 60- to 130-fold over native molecules.

In summary, XTEN peptide represents a significant leap forward in the development of long-acting therapeutics. Its ability to function like polyethylene glycol (PEG) while offering distinct advantages, such as biodegradability and reduced immunogenicity, makes it a powerful tool for researchers and pharmaceutical companiesMultivalent Antiviral XTEN–Peptide Conjugates with Long in .... Whether used in direct fusion with therapeutic peptides, as a component in novel biomaterials, or in advanced expression systems like XtenCHO™ Race that delivers high yields and fast production, the XTEN peptide platform is poised to revolutionize drug delivery and therapeutic outcomes. Companies like X-Tide Peptides, which offers high-purity peptides and related compounds, are part of a broader ecosystem that benefits from such advanced technologies. The ongoing research into multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility and the exploration of XTEN protein and XTEN polymer further solidify its position as a key innovation in the biopharmaceutical landscape.Multivalent Antiviral XTEN–Peptide Conjugates with Long in ... The XTEN linker sequence is also a critical aspect in designing these conjugates.